Jeito Capital II
Share
N°01 / About
About Jeito Capital II
Jeito Capital II is a ~€1 billion ($1.2B) biopharma venture fund — Europe's largest independent biopharma venture vehicle ever raised. Backs 15–20 clinical-stage companies in obesity, oncology, immunology, neurology, and cardio-metabolic disease with ~€150M average tickets. Fund I generated exits to Merck and Biogen totalling up to $4.8B.
N°02 / Thesis
Investment Focus
Location / RegionFrance
Funding StageLate Stage
Industry Focus
Therapeutics
Investor Signals Profile
active
Sweet Spot
European clinical-stage biotech CEO with Phase 2/3 asset in high-unmet-need disease area
24 signals on Jeito Capital II
7 bullish · 3 contrarian · 5 pitch do's · 3 don'ts · 6 GP profiles, each with its source. From €9/month, cancel anytime.
Michael's Network
People
Key People
Jeito Capital
Dr. Rafaèle TordjmanFounder & Managing Partner
Rafaèle TordjmanFounder & CEO (Managing Partner per known list)
Sabine DandiguianManaging Partner
Ksenija PavleticGeneral Partner & Chief Commercial Officer
Mehdi AinouchePartner
Pascal TouchonPartner